Speakers
Biomedical Stream
International Speakers
Professor Jeremy Shefner
Barrow Neurological Institute, USA
Global MND/ALS clinical trials update
&
Clinical Trial Design for ALS Trials
Professor Ammar Al-Chalabi
Kings College, London
What causes MND? – genetics, epidemiology, and disease modelling
Professor Stanley Appel
Houston Methodist Neurological Institute , USA
Suppressing Neuroinflammation: Cell-Based Therapy in ALS
Dr Lucie Bruijn
Chief Scientist ALSA, USA
Opportunities and Advances in Drug Development For ALS
Professor Michael Benatar
Uni. of Miami, USA
The Role of Biomarkers in ALS Therapy Development
Professor Luis Barbeito
Institut Pasteur de Montvideo , Uruguay
Cellular targets of masitinib in a rat ALS model
Australian Speakers
Professor Naomi Wray
Uni. of Queensland, AUS
Big ‘omics data in ALS: Current results and future prospects
Professor Robert Henderson
Uni. of QLD, AUS
A Phase I Australian clinical trial of an immunotherapeutic drug in MND/ALS patients
Dr Joseph Nicolazzo
Monash Uni, AUS
The blood-brain barrier: an obstacle for CNS drug delivery impacted by motor neurone disease
Assoc. Professor Paul Talman
Deakin Uni, AUS
Australian MND Registry; What 14 years of data-collection has taught us about MND/ALS